Abstract: An electric vacuum jet engine is a more ecofriendly alternative to gas-fueled jet engines that generates the same or higher thrust than traditional gas-fueled jet engines. The jet engine includes a tubular housing, at least one first propeller assembly, and at least one second propeller assembly. The tubular housing accommodates an alternating of series of propeller assemblies formed by the at least one first propeller assembly and the at least one second propeller assembly. Together, the at least one first propeller assembly and the at least one second propeller assembly generate several vacuums along the tubular housing that increase the velocity of air flow through the tubular housing to generate the thrust necessary to propel the desired aircraft. The tubular housing also includes a housing inlet and a housing outlet corresponding to the open ends of the tubular housing through which air flow enters and exits the tubular housing, respectively.

Abstract: Gracilin A congeners and methods for their use as immunosuppressive and neuroprotective agents.

Abstract: Pateamine A derivatives, pharmaceutical compositions that include the derivatives, and methods for treating chronic lymphocytic leukemia using the derivatives.

Abstract: Gracilin A congeners and methods for their use as immunosuppressive and neuroprotective agents.

Abstract: Pateamine A derivatives and pharmaceutical compositions that include the derivatives. The pateamine A derivatives are ?-amino pateamine A derivatives that lack the C5-methyl group of pateamine A.

Abstract: Implementations described herein include a device including a stimulation transducer operably coupled to a stimulation controller. The stimulation transducer focally delivers energy to a target tissue at a selected depth below the surface of the skin of a subject and the stimulation controller generates a signal indicating a selected pulse intensity, a selected pulse duration, and a selected treatment session duration sufficient to heat the target tissue to a temperature from 40 to 45 degrees Celsius via application of energy by the stimulation transducer.

Abstract: A passenger-carrying rotorcraft with fixed-wings for generating lift utilizes an occupiable structural body, a control unit, a plurality of lift-generating rotors, a portable power source, and a bi-wing structure. The rotorcraft configured with fixed-wings results in an energy-efficient aircraft capable of vertical takeoff and landing. The occupiable structural body is designed to carry a pilot and one or more passengers. The control unit is wired to flight instruments controlled by the pilot, allowing the pilot to maneuver the rotorcraft. The plurality of lift-generating rotors provides upward thrust for vertical takeoff and landing of the rotorcraft. The portable power source is charged by a hybrid power generation system running on both renewable solar energy and a non-renewable chemical fuel source. The bi-wing structure employs two airfoils positioned on top of each other to maximize the lift without significantly increasing the effective wingspan.

Abstract: Pateamine A derivatives and pharmaceutical compositions that include the derivatives. The pateamine A derivatives are ?-amino pateamine A derivatives that lack the C5-methyl group of pateamine A.

Abstract: Pateamine A derivatives and pharmaceutical compositions that include the derivatives. The pateamine A derivatives are ?-amino pateamine A derivatives that lack the C5-methyl group of pateamine A.

Abstract: Pateamine A derivatives, pharmaceutical compositions that include the derivatives, and methods for treating chronic lymphocytic leukemia using the derivatives.

Abstract: Implementations described herein include a device including a stimulation transducer operably coupled to a stimulation controller. The stimulation transducer focally delivers energy to a target tissue at a selected depth below the surface of the skin of a subject and the stimulation controller generates a signal indicating a selected pulse intensity, a selected pulse duration, and a selected treatment session duration sufficient to heat the target tissue to a temperature from 40 to 45 degrees Celsius via application of energy by the stimulation transducer.

Abstract: A passenger-carrying rotorcraft with fixed-wings for generating lift utilizes an occupiable structural body, a control unit, a plurality of lift-generating rotors, a portable power source, and a bi-wing structure. The rotorcraft configured with fixed-wings results in an energy-efficient aircraft capable of vertical takeoff and landing. The occupiable structural body is designed to carry a pilot and one or more passengers. The control unit is wired to flight instruments controlled by the pilot, allowing the pilot to maneuver the rotorcraft. The plurality of lift-generating rotors provides upward thrust for vertical takeoff and landing of the rotorcraft. The portable power source is charged by a hybrid power generation system running on both renewable solar energy and a non-renewable chemical fuel source. The bi-wing structure employs two airfoils positioned on top of each other to maximize the lift without significantly increasing the effective wingspan.

Abstract: Pateamine A derivatives and pharmaceutical compositions that include the derivatives. The pateamine A derivatives are ?-amino pateamine A derivatives that lack the C5-methyl group of pateamine A.

Abstract: Provided herein include compositions, all related stereoisomers as well as pharmaceutically acceptable salts provided as simplified analogs of pateamine A, in which the analogs generally are devoid of the C3-amino and C5-methyl groups, also referred to as desmethyl, desamino-pateamine A. Suitable analogs provide anticancer and antiproliferative effects in vivo and in vitro by a novel drugs mechanism of action described herein for pateamine A, including inhibition of eIF4A-dependent translation initiation. As with pateamine A, as described herein, suitable analogs cause cell cycle arrest or induce apoptosis in transformed cells. However, toxicity of such compounds to slow growing normal cells is low. In addition, such analogs, like pateamine A, target translation initiation factors and are useful as anticancer and antiproliferative agents in subjects in need thereof.

Abstract: The present invention provides compounds having the general structure A, or a pharmaceutically acceptable derivatives thereof: wherein R is an alkyl group, and R1 comprises at least one moiety selected from a group consisting of an alkyl, an alkenyl, an aryl, a heterocycle, hydroxyl, ester, amido, aldehyde, and a halogen.

Abstract: The present invention features methods of treating a cancer in a subject by administering an effective amount of a beta-lactone to the subject. The invention also features methods of inhibiting angiogenesis in a subject by administering an effective amount of an inhibitor of fatty acid synthase to the subject. These methods can be used to treat a variety of cancers and other diseases and conditions. The invention also features methods of identifying beta-lactones and other compounds that can be used in the methods of the invention for the treatment of tumors, inhibition of angiogenesis, and the treatment of diseases and conditions that involve pathological angiogenesis. The invention also features methods of synthesizing beta-lactones and features novel beta-lactone compounds.

Abstract: Derivatives of belactosin and their synthesis are disclosed. In certain embodiments, compounds of the present invention exhibit anti-cancer, antiviral, antibiotic, and/or auto-immune therapeutic abilities. In general, methods of synthesis disclosed herein allow for introduction of a variety of substituents at numerous positions as well as the facile introduction of a beta-lactone ring moiety. The synthetic steps comprise, in preferred embodiments, a tandem Mukaiyama aldol lactonization reaction. Data demonstrating the utility of some of the derivatives as proteasome inhibitors is also disclosed.

Abstract: The present invention provides a concise synthetic method for generating lactam-fused beta-lactones that feature, in some embodiments, a tertiary fused carbinol, quaternary carbons, and a reactive beta-lactone moiety available for further reactions. The present invention further provides compounds synthesized by this method as well as methods of using these compounds as inhibitors of the proteasome and fatty acid synthase.

Abstract: The present invention is directed toward a method for determination of marinobufagenin concentration in a body specimen through conjugation of marinobufagenin to a suitable protein, thereby creating a conjugate which will trigger an antibody response in a host. The conjugated marinobufagenin is immunogenic. The antibodies so produced may be employed in an ELISA test to ascertain the concentration of marinobufagenin in a body specimen. A number of unique compounds are created in the process and are disclosed. An ELISA assay may be employed.